[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"m-teer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:m-teer":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,51],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":32,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100609357","enhanced-valves-interventions-and-safe-ai-generated-end-results-100609357",false,"NCT07213531","Enhanced Valves Interventions and Safe AI Generated End Results","ENVISAGE","Inclusion Criteria:\n\nPatients who have reached the age of legal majority under local laws.\n\n* For TAVI group: All patients who have had TAVI with a third generation transcatheter heart valve (THV), with an available pre-procedural optimal quality CT scan as defined by an ECG- gating CT with:\n\n  1. five to ten image volumes at cardiac phases from 5% to 95% R-R\n  2. 0.625 mm slice thickness\n  3. 0.625 mm spacing between slices\n  4. 0.88 mm in-plane pixel spacing\n* For TMVI group: Patients who have had a TMVI with a dedicated device and screen failures, with an available optimal quality CT scan.\n* For TTVI group: Patients who have had a TTVI with a dedicated device and screen failures, with an available optimal quality CT scan.\n* For M-TEER: All patient who have had a M-TEER with 1) G4 or newer iteration of MitraClip or 2) G2 or newer iteration of Pascal, with available pre-procedural TEE videos images from one of two vendors: Phillips or GE, with clear identifiable views of the Mitral valve, frame per second equal or higher than 40 frames per second, acceptable 3D reconstructions.\n* For T-TEER: All patient who have had a T-TEER with G4 or newer iteration of TriClip or 2) G2 or newer iteration of Pascal, with available pre-procedural TEE videos images from one of two vendors: Phillips or GE, with clear identifiable views of the Tricuspid valve, frame per second equal or higher than 40 frames per second, acceptable transgastric image with acceptable 3D reconstructions.\n\nExclusion Criteria:\n\n* For TAVI group: Valve-in-valve procedures\n* For TMVI group: Valve-in-valve and valve-in-ring procedures\n* For TTVI: Valve-in-valve and valve-in-ring procedures\n* For M-TEER: G3 or older MitraClip, G1 Pascal\n* For T-TEER: G3 Triclip, G1 Pascal","ALL","18 Years",{"count":19,"type":20},21000,"ESTIMATED","OBSERVATIONAL","This non-interventional study aims to use artificial intelligence to improve the prediction of transcatheter heart valve interventions and optimize patient outcomes. It is based on the analysis of retrospective data from various specialized centers worldwide.",[24,25,26,27,28,29,30,31],"Heart Valve Disease","TAVI","M-TEER","TTVI","TMVI","T-TEER","Mitraclip","TriClip",[33,34,35,26,29,25,28,36,37],"Medical imaging","CT","Artificial intelligence","valvulopathy","predictive algorithms","RECRUITING","2025-10-01",{"date":41,"type":42},"2025-10-09","ACTUAL",{"date":44,"type":42},"2024-05-01",{"date":46,"type":20},"2029-05",{"name":48,"class":49},"Montreal Heart Institute","OTHER",15,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":59,"targetDuration":61,"studyType":21,"phases":4,"briefSummary":62,"conditions":63,"keywords":66,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":81},"100570075","optimizing-clinical-outcomes-in-patients-undergoing-mitral-transcatheter-edge-to-edge-repair-m-teer-for-severe-functional-mitral-regurgitation-towards-improved-guideline-directed-medical-therapy-100570075","NCT06702527","Optimizing Clinical Outcomes in Patients Undergoing Mitral Transcatheter Edge-to-edge Repair (M-TEER) for Severe Functional Mitral Regurgitation Towards Improved Guideline-directed Medical Therapy","Optimizing Clinical Outcomes in Patients Undergoing M-TEER for Severe Functional Mitral Regurgitation Towards Improved Guideline-directed Medical Therapy - The MOTOR Registry","MOTOR","Inclusion Criteria:\n\n* mitral transcatheter edge-to-edge repair (M-TEER) patients treated with the PASCAL system (≥ 18 years) as per the current approved indication and local Heart Team decision\n* Severe functional and mixed-type mitral regurgitation with LV-EF \\\u003C 50%\n* Patient with optimized guideline-directed medical therapy (GDMT): A minimum of 3 points in the pre-defined GMDT scoring system\n* Provision of written informed consent\n\nExclusion Criteria:\n\n* Degenerative mitral regurgitation\n* Emergency procedure\n* Re-do or concomitant (mitral\u002Ftricuspid) procedures\n* Patients on maximum dose GDMT\n* Atrial functional mitral regurgitation (FMR)\n* Coronary revascularisation within the last 3 months\n* Pregnant woman",{"count":60,"type":20},100,"12 Months","A multi-centre, prospective, observational pilot registry in patients undergoing mitral valve repair for severe functional mitral regurgitation to report the heart failure drug therapy and dosing before the mitral valve procedure and afterwards to assess whether the recommended maximal dose of medication is administered. This maximal dose, although recommended, might not be tolerated well by patients and can cause side-effects. Researchers will determine whether the mitral valve repair procedure might have a possible effect on increasing the drug therapy towards the recommended optimal doses.",[64,65,26],"Mitral Regurgitation Functional","Heart Failure",[67,65,26,68,69],"Mitral Regurgitation","Optimizing GDMT","Functional Mitral Regurgitation","NOT_YET_RECRUITING","2025-05-20",{"date":73,"type":42},"2025-05-23",{"date":75,"type":20},"2025-06-01",{"date":77,"type":20},"2026-09-01",{"name":79,"class":80},"Institut für Pharmakologie und Präventive Medizin","NETWORK",1]